- Home
- RNAZ vs ADIL Comparison
RNAZ vs ADIL Comparison
Compare RNAZ & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- ADIL
- Stock Information
- Founded
- RNAZ 2016
- ADIL 2010
- Country
- RNAZ United States
- ADIL United States
- Employees
- RNAZ N/A
- ADIL N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- ADIL Biotechnology: Pharmaceutical Preparations
- Sector
- RNAZ Health Care
- ADIL Health Care
- Exchange
- RNAZ Nasdaq
- ADIL Nasdaq
- Market Cap
- RNAZ 8.7M
- ADIL 7.7M
- IPO Year
- RNAZ 2021
- ADIL 2018
- Fundamental
- Price
- RNAZ $15.00
- ADIL $0.40
- Analyst Decision
- RNAZ Strong Buy
- ADIL Strong Buy
- Analyst Count
- RNAZ 1
- ADIL 2
- Target Price
- RNAZ $280.00
- ADIL $4.75
- AVG Volume (30 Days)
- RNAZ 13.8K
- ADIL 737.3K
- Earning Date
- RNAZ 11-13-2025
- ADIL 11-12-2025
- Dividend Yield
- RNAZ N/A
- ADIL N/A
- EPS Growth
- RNAZ N/A
- ADIL N/A
- EPS
- RNAZ N/A
- ADIL N/A
- Revenue
- RNAZ N/A
- ADIL N/A
- Revenue This Year
- RNAZ N/A
- ADIL N/A
- Revenue Next Year
- RNAZ N/A
- ADIL N/A
- P/E Ratio
- RNAZ N/A
- ADIL N/A
- Revenue Growth
- RNAZ N/A
- ADIL N/A
- 52 Week Low
- RNAZ $6.15
- ADIL $0.22
- 52 Week High
- RNAZ $739.20
- ADIL $1.30
- Technical
- Relative Strength Index (RSI)
- RNAZ 84.37
- ADIL 58.88
- Support Level
- RNAZ $10.32
- ADIL $0.37
- Resistance Level
- RNAZ $12.28
- ADIL $0.41
- Average True Range (ATR)
- RNAZ 0.87
- ADIL 0.02
- MACD
- RNAZ 0.57
- ADIL 0.01
- Stochastic Oscillator
- RNAZ 91.34
- ADIL 75.00
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.